These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

514 related articles for article (PubMed ID: 27101868)

  • 1. TP53 hotspot mutations are predictive of survival in primary central nervous system lymphoma patients treated with combination chemotherapy.
    Munch-Petersen HD; Asmar F; Dimopoulos K; Areškevičiūtė A; Brown P; Girkov MS; Pedersen A; Sjö LD; Heegaard S; Broholm H; Kristensen LS; Ralfkiaer E; Grønbæk K
    Acta Neuropathol Commun; 2016 Apr; 4():40. PubMed ID: 27101868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diffuse large B-cell lymphoma with combined TP53 mutation and MIR34A methylation: Another "double hit" lymphoma with very poor outcome?
    Asmar F; Hother C; Kulosman G; Treppendahl MB; Nielsen HM; Ralfkiaer U; Pedersen A; Møller MB; Ralfkiaer E; de Nully Brown P; Grønbæk K
    Oncotarget; 2014 Apr; 5(7):1912-25. PubMed ID: 24722400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical aspects of TP53 gene inactivation in diffuse large B-cell lymphoma.
    Voropaeva EN; Pospelova TI; Voevoda MI; Maksimov VN; Orlov YL; Seregina OB
    BMC Med Genomics; 2019 Mar; 12(Suppl 2):35. PubMed ID: 30871527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aberrant methylation in the promoter region of the reduced folate carrier gene is a potential mechanism of resistance to methotrexate in primary central nervous system lymphomas.
    Ferreri AJ; Dell'Oro S; Capello D; Ponzoni M; Iuzzolino P; Rossi D; Pasini F; Ambrosetti A; Orvieto E; Ferrarese F; Arrigoni G; Foppoli M; Reni M; Gaidano G
    Br J Haematol; 2004 Sep; 126(5):657-64. PubMed ID: 15327516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methotrexate-cytarabine-dexamethasone combination chemotherapy with or without rituximab in patients with primary central nervous system lymphoma.
    Sun X; Liu J; Wang Y; Bai X; Chen Y; Qian J; Zhu H; Liu F; Qiu X; Sun S; Ji N; Liu Y
    Oncotarget; 2017 Jul; 8(30):49156-49164. PubMed ID: 28467782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.
    Berns EM; Foekens JA; Vossen R; Look MP; Devilee P; Henzen-Logmans SC; van Staveren IL; van Putten WL; Inganäs M; Meijer-van Gelder ME; Cornelisse C; Claassen CJ; Portengen H; Bakker B; Klijn JG
    Cancer Res; 2000 Apr; 60(8):2155-62. PubMed ID: 10786679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary central nervous system lymphoma: Retrospective analysis of 34 cases in a single centre.
    Wang H; Wang M; Wei J; Wang L; Mao L; Jin J
    J Int Med Res; 2018 Feb; 46(2):883-894. PubMed ID: 28984175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The influence of rituximab, high-dose therapy followed by autologous stem cell transplantation, and age in patients with primary CNS lymphoma.
    Madle M; Krämer I; Lehners N; Schwarzbich M; Wuchter P; Herfarth K; Egerer G; Ho AD; Witzens-Harig M
    Ann Hematol; 2015 Nov; 94(11):1853-7. PubMed ID: 26268792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interim
    Jo JC; Yoon DH; Kim S; Lee K; Kang EH; Park JS; Ryu JS; Huh J; Park CS; Kim JH; Lee SW; Suh C
    Ann Hematol; 2017 Sep; 96(9):1509-1515. PubMed ID: 28725988
    [No Abstract]   [Full Text] [Related]  

  • 10. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial.
    Thiel E; Korfel A; Martus P; Kanz L; Griesinger F; Rauch M; Röth A; Hertenstein B; von Toll T; Hundsberger T; Mergenthaler HG; Leithäuser M; Birnbaum T; Fischer L; Jahnke K; Herrlinger U; Plasswilm L; Nägele T; Pietsch T; Bamberg M; Weller M
    Lancet Oncol; 2010 Nov; 11(11):1036-47. PubMed ID: 20970380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of rituximab in treatment of patients with primary central nervous system lymphoma: a retrospective analysis of the Czech lymphoma study group registry.
    Mocikova H; Pytlik R; Sykorova A; Janikova A; Prochazka V; Vokurka S; Berkova A; Belada D; Campr V; Buresova L; Trneny M;
    Leuk Lymphoma; 2016 Dec; 57(12):2777-2783. PubMed ID: 27087066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab, methotrexate, procarbazine, vincristine and intensified cytarabine consolidation for primary central nervous system lymphoma (PCNSL) in the elderly: a LOC network study.
    Houillier C; Ghesquières H; Chabrot C; Soussain C; Ahle G; Choquet S; Nicolas-Virelizier E; Bay JO; Vargaftig J; Gaultier C; Touitou V; Martin-Duverneuil N; Cassoux N; Le Garff-Tavernier M; Costopoulos M; Faurie P; Hoang-Xuan K
    J Neurooncol; 2017 Jun; 133(2):315-320. PubMed ID: 28432587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BCL-6 expression predicts improved survival in patients with primary central nervous system lymphoma.
    Braaten KM; Betensky RA; de Leval L; Okada Y; Hochberg FH; Louis DN; Harris NL; Batchelor TT
    Clin Cancer Res; 2003 Mar; 9(3):1063-9. PubMed ID: 12631608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TP53 mutation and survival in chronic lymphocytic leukemia.
    Zenz T; Eichhorst B; Busch R; Denzel T; Häbe S; Winkler D; Bühler A; Edelmann J; Bergmann M; Hopfinger G; Hensel M; Hallek M; Döhner H; Stilgenbauer S
    J Clin Oncol; 2010 Oct; 28(29):4473-9. PubMed ID: 20697090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of hypermethylation of death-associated protein kinase (DAPK) gene CpG island in dogs with high-grade B-cell lymphoma.
    Sato M; Mochizuki H; Goto-Koshino Y; Fujiwara-Igarashi A; Takahashi M; Ohno K; Tsujimoto H
    Vet Comp Oncol; 2018 Sep; 16(3):409-415. PubMed ID: 29527805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A focus on pharmacotherapy for primary central nervous system lymphoma.
    Korfel A
    Expert Rev Hematol; 2015 Oct; 8(5):559-62. PubMed ID: 26159859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differentially regulated miRNAs as prognostic biomarkers in the blood of primary CNS lymphoma patients.
    Roth P; Keller A; Hoheisel JD; Codo P; Bauer AS; Backes C; Leidinger P; Meese E; Thiel E; Korfel A; Weller M
    Eur J Cancer; 2015 Feb; 51(3):382-90. PubMed ID: 25534293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
    Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
    Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma.
    Korfel A; Thiel E; Martus P; Möhle R; Griesinger F; Rauch M; Röth A; Hertenstein B; Fischer T; Hundsberger T; Mergenthaler HG; Junghanß C; Birnbaum T; Fischer L; Jahnke K; Herrlinger U; Roth P; Bamberg M; Pietsch T; Weller M
    Neurology; 2015 Mar; 84(12):1242-8. PubMed ID: 25716362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.
    Mappa S; Marturano E; Licata G; Frezzato M; Frungillo N; Ilariucci F; Stelitano C; Ferrari A; Sorarù M; Vianello F; Baldini L; Proserpio I; Foppoli M; Assanelli A; Reni M; Caligaris-Cappio F; Ferreri AJ
    Hematol Oncol; 2013 Sep; 31(3):143-50. PubMed ID: 23161567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.